Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

This update describes an ongoing Phase 2 trial of ibrutinib for relapsed hairy cell leukemia and hairy cell leukemia variant. The study is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia
• Hairy Cell Leukemia Variant

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Status: ACTIVE_NOT_RECRUITING